Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma

Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) incidence, as well as related mortality, has been steadily increasing in the USA and across the globe, partly due to the lack of effective therapeutic options for advanced HCC. Though sorafenib is considered standard-of-care for advanced HCC, it only improves median su...

Full description

Bibliographic Details
Main Authors: Sumit Siddharth, Panjamurthy Kuppusamy, Qitong Wu, Arumugam Nagalingam, Neeraj K. Saxena, Dipali Sharma
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:International Journal of Molecular Sciences
Subjects:
hepatocellular carcinoma
combination treatment
sorafenib
metformin
MAPK
ERK
Online Access:https://www.mdpi.com/1422-0067/23/15/8083

Internet

https://www.mdpi.com/1422-0067/23/15/8083

Similar Items